Cleveland BioLabs Financials

Cleveland BioLabs Stock Summary

Cleveland BioLabs competes with Visionary Education, Braskem SA, Alto Ingredients, Avient Corp, and GMéxico Transportes. Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. The company was incorporated in 2003 and is headquartered in Buffalo, New York. Cleveland Biolabs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.

Cleveland BioLabs Key Financial Ratios

Generally speaking, Cleveland BioLabs' financial ratios allow both analysts and investors to convert raw data from Cleveland BioLabs' financial statements into concise, actionable information that can be used to evaluate the performance of Cleveland BioLabs over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cleveland BioLabs reports annually and quarterly.

Cleveland Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cleveland BioLabs's current stock value. Our valuation model uses many indicators to compare Cleveland BioLabs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cleveland BioLabs competition to find correlations between indicators driving Cleveland BioLabs's intrinsic value. More Info.Cleveland BioLabs is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cleveland BioLabs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cleveland BioLabs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cleveland BioLabs' earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

If you are still planning to invest in Cleveland BioLabs check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cleveland BioLabs' history and understand the potential risks before investing.